Ernest Mceachern
President & CEO
Business Development
Alectos Therapeutics
Canada
Biography
Dr. McEachern received his PhD from the University of British Columbia and carried out postdoctoral studies at Stanford University. Dr. McEachern has over seventeen years experience in scientific and leadership roles in the pharmaceutical industry. He served in various capacities at AnorMED Inc. including leading a team in preclinical development of CXCR4 and CCR5 chemokine receptor antagonists as HIV entry inhibitors; these efforts culminated in Phase II clinical evaluation of the lead candidate AMD070. Dr. McEachern is a co-founder of Alectos Therapeutics and directed the scientific and business development activities that led to the $289M license and research collaboration agreement between Alectos and Merck & Co., Inc. He is President and Chief Executive Officer of Alectos Therapeutics and has served as a member of the Board of Directors since founding the company. Dr. McEachern is co-author on over 60 publications and patents.
Research Interest
Business Development
